Pioneering AAV-Delivered T-Cell Immunotherapy To
Transform
the Treatment
Of Cancer
About Vironexis
Realizing the Full Potential of T-cell Immunotherapy
T-cell and other immunotherapies have represented a major medical advance for certain types of cancer. However, existing technologies are associated with various shortcomings that translate to safety and efficacy challenges, burdensome treatment regimens, and an impracticality of scaling customized therapies for large patient populations.
Our AAV-delivered T-cell Immunotherapy builds on the power of T-cell immunotherapy while leveraging AAV delivery to overcome the shortcomings and challenges of existing approaches. We aim to revolutionize the immunotherapy landscape and transform the treatment of cancer.
Off-the-shelf, single-dose AAV gene therapy enables durable T-cell-mediated tumor killing
With our TransJoin™ AAV Gene Therapy Platform, we are creating off-the-shelf T-cell immuno-gene therapies delivered via a one-time infusion and without the need for pre-treatment or custom-manufacturing.
TransJoin enables the expression of an engineered transgene that redirects T cells throughout the body to tumor cells and provides a bridge that joins them together, promoting steady-state, durable T-cell-mediated tumor killing.
About Vironexis
Pipeline
We’re working to quickly advance important treatment options for patients. To date, we’ve built a pipeline of 10+ product candidates for blood-based cancers, solid tumor metastasis prevention, and cancer prevention through a vaccine.
Pillar 1 – Blood Based Cancer
VNX-101
FDA Fast Track Designation
FDA Rare Pediatrics Designation
FDA Orphan Drug Designation
VNX-102
VNX-103
Pillar 2 – Solid Tumors
VNX-201
VNX-202
VNX-203
VNX-204
VNX-205
VNX-206
VNX-207
VNX-208
Pillar 3 – Cancer Prevention
VNX-301
Partner Programs
VNX-101-2*
*Vironexis plans to partner this program for further development.
Visionary
Gene therapy & Oncology Pioneers
Our founding team has deep expertise in successful gene therapy development, cutting-edge oncology research, and company formation. We’ve combined our know-how to change the paradigm in cancer treatment outcomes.